OBI Pharma's GlycOBI® Platform Gains Attention at Nanjing Summit
Optimized Process Design and CMC: Key to Next-Generation ADC Development

OBI Pharma (4174.TWO) has been invited to present at the "8th Antibody and ADC Deep Focus Summit (Antibody China 2025)" held in Nanjing, China on the 27th and 28th of February. The presentation will showcase the development of next-generation Antibody-Drug Conjugates (ADCs), detailing how the enhancement in the process design can successfully deliver Chemistry, Manufacturing, and Controls (CMC) objectives, and sharing insights on the approaches taken to design these advanced ADCs.